Reading Time: 7 minutesGlobal biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in
Tag: phase 3
Reading Time: 2 minutesThis blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters